Eris Lifesciences has formally notified the stock exchanges about its upcoming board meeting scheduled for February 13, 2026. The meeting will focus on reviewing and approving the company's quarterly financial performance for the third quarter of fiscal year 2026.

Board Meeting Details

The pharmaceutical company's Board of Directors will convene to consider and approve both standalone and consolidated unaudited financial results. The meeting will cover the financial performance for two key periods:

Trading Window Restrictions

Eris Lifesciences has implemented trading window restrictions in accordance with regulatory requirements. The company had previously informed stakeholders about these measures through its communication dated December 29, 2025.

Regulatory Compliance

The trading window closure aligns with the company's internal policy on 'Code of Conduct to Regulate, Monitor and Report Trading by its Designated Persons and immediate relatives of Designated Persons of the Company'. This measure ensures compliance with SEBI's insider trading regulations and maintains market integrity during the financial results announcement period.

Corporate Communication

The official notification was signed by Milind Talegaonkar, Company Secretary & Compliance Officer, and submitted to both BSE Limited and National Stock Exchange of India Limited. The company trades under security code 540596 on BSE and under the symbol ERIS on NSE.

Investors and stakeholders will need to wait until the board meeting concludes and results are officially declared before normal trading activities can resume for designated persons associated with the company.

Eris Lifesciences Limited has successfully concluded its postal ballot voting process, with all four proposed resolutions receiving shareholder approval through remote e-voting that ended on December 24, 2025.

Postal Ballot Process Overview

The remote e-voting period commenced at 09:00 a.m. IST on November 25, 2025, and remained open until 17:00 hours IST on December 24, 2025. The company had initially issued the Postal Ballot Notice on November 24, 2025, which was subsequently updated through corrigenda dated December 5, 2025, and December 17, 2025.

Resolution Results Summary

All four resolutions were passed with overwhelming support from shareholders. The voting results demonstrate strong confidence from both promoter and public shareholders across different categories.

Resolution 1: Re-appointment of Whole-Time Director

The special resolution for re-appointing Mr. Krishnakumar Vaidyanathan as Whole-Time Director received substantial approval:

Resolution 2: Re-appointment of Independent Director

The special resolution to re-appoint Ms. Kalpana Unadkat as Independent Director also secured approval:

Resolution 3: Preferential Share Issuance

The special resolution for approval of issuance up to 23,06,372 fully paid-up equity shares on preferential basis for consideration other than cash received near-unanimous support:

Resolution 4: Related Party Transactions

The ordinary resolution to approve material related party transactions with Mr. Naishadh Shah was passed with strong support:

Compliance and Documentation

The voting results have been prepared in compliance with Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. All relevant documents, including the e-voting results and scrutinizer's report, have been uploaded on the company's website and the website of MUFG Intime India Private Limited, the registrar and transfer agent.

The successful completion of this postal ballot process enables Eris Lifesciences to proceed with its planned corporate actions, including the key appointments and the preferential share issuance, supporting the company's strategic initiatives.